# Progress Note 04 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Vincent van Gogh (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI010-SYN-TD
- Date: 1889-03-02
- Fictional facility: St. Posthumous Health Center
- Fictional author: Elise Verhoeven, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Six-week review: symptoms, side effects, alcohol, sleep, and test results. **S**

## History of present illness

Mr. van Gogh returns six weeks after his first visit and two weeks after the sick visit for akathisia, when aripiprazole went back to 10 mg and propranolol was started. The restlessness eased within three days and has been gone for more than a week. The night-time voices have not returned on 10 mg. He sleeps six and a half to seven hours. He is painting again for a few hours most days, which he says matters more to him than anything. He takes naltrexone daily and now has one or two glasses of wine on most evenings; he notices that he wants a second glass less. His mood is better, and the thoughts of not waking up have stopped. He meets the care coordinator weekly and has seen the therapist twice. **S**

| Element | Detail |
|---|---|
| Aripiprazole | 10 mg daily for two weeks, every dose taken |
| Akathisia | Resolved within three days; propranolol 10 mg twice daily |
| Psychotic symptoms | None |
| Sleep | Six and a half to seven hours |
| Alcohol | One or two glasses of wine most evenings |
| Mood | Better; PHQ-9 8; item 9 scored 0 |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Neurological | Negative | No restlessness, stiffness, tremor, seizures, or lost time |
| Cardiovascular | Negative | No dizziness or fainting on propranolol |
| Gastrointestinal | Negative | Mild nausea in the first days of naltrexone, now gone |
| Psychiatric | Negative | No voices or suspiciousness; mood improving; no thoughts of suicide or self-harm |

4 systems reviewed. **S**

## Current medications

- Naltrexone 50 mg oral tablet, one tablet by mouth once daily **S**
- Thiamine 100 mg oral tablet, one tablet by mouth daily (started in hospital) **S**
- Aripiprazole 10 mg oral tablet, one tablet by mouth once daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 120/76 mmHg; pulse 76 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 64.9 kg; BMI 22.5 kg/m². All vital signs are synthetic.

AST: 41 U/L (high); ALT: 37 U/L; GGT: 68 U/L (high); Phosphatidylethanol (PEth): 122 ng/mL (high); PHQ-9: 8. All results are synthetic.

## Change since baseline

- AST: 58 U/L (high) at baseline, 41 U/L (high) at this visit **S**
- ALT: 44 U/L at baseline, 37 U/L at this visit **S**
- GGT: 96 U/L (high) at baseline, 68 U/L (high) at this visit **S**
- Phosphatidylethanol (PEth): 284 ng/mL (high) at baseline, 122 ng/mL (high) at this visit **S**
- PHQ-9: 13 at baseline, 8 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 64.9 kg; blood pressure 120/76, pulse 76 |
| Neurological | No akathisia (Barnes global rating 0), rigidity, tremor, or abnormal movements |
| Psychiatric | Brighter affect; organized; no psychotic features; insight good |

All examination findings are synthetic. **S**

## Assessment and plan

1. **First episode of psychosis with mood features, provisional diagnosis** (F29). Remission of psychotic symptoms on aripiprazole 10 mg. The brain MRI was normal, and the sleep-deprived EEG showed no epileptiform discharges; a normal EEG does not exclude focal epilepsy, but with no seizure-like events the team will not test further unless such events occur. Safety reviewed: no thoughts of suicide or self-harm; the safety plan is current. **S**
   - Continue aripiprazole 10 mg daily.
   - Report any episodes of lost time, odd smells or tastes, or sudden fear, which would reopen the question of seizures.
2. **Akathisia** (G25.71). Resolved on the lower dose. **S**
   - Stop propranolol today.
3. **Alcohol use disorder on naltrexone** (F10.20). PEth down from 284 to 122 ng/mL; AST 41, ALT 37 and GGT 68 U/L, improving on naltrexone. **S**
   - Continue naltrexone and thiamine.
   - His own goal: no more than one glass of wine with dinner, and none on two days a week.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Medication safety | Antipsychotic dose, adherence, and response | Every visit | Completed today | Aripiprazole 10 mg since the sick visit; full adherence; remission of psychotic symptoms |
| Survey | Psychotic and mood symptoms, and early warning signs | Every visit | Completed today | No hallucinations or suspiciousness; no early warning signs |
| Examination | Akathisia, parkinsonism, and sedation | Every visit in the first months and after any dose change | Completed today | Akathisia resolved; no parkinsonism or sedation; propranolol stopped |
| Examination | Weight and BMI | Every visit for 6 months after starting, then quarterly (CMID: baseline, 4, 8, and 12 weeks, then quarterly) | Completed today | 64.9 kg at eight weeks, from 64.0 |
| Examination | Blood pressure | Baseline, 12 weeks, then yearly | Completed today | 120/76 |
| Laboratory | Fasting glucose and A1c | Baseline, 12 weeks to 4 months, then yearly | Up to date | Next at the three-month visit |
| Laboratory | Fasting lipid panel | Baseline, 12 weeks to 4 months, then yearly | Up to date | Next at the three-month visit |
| Laboratory | First-episode workup (MRI and EEG) | Once, in the first-episode workup | Completed today | Brain MRI normal; sleep-deprived EEG without epileptiform discharges |
| Survey | Depression measure (PHQ-9) | Monthly during acute treatment, every 2 to 4 weeks in continuation, then periodically | Completed today | PHQ-9 8, item 9 scored 0 |
| Survey | Suicide-risk review, safety plan, lethal means, and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm; safety plan current; the 988 Suicide & Crisis Lifeline in his phone |
| Self-management | Sleep | Every visit | Completed today | Six and a half to seven hours at regular times |
| Survey | Drinking (AUDIT-C and PEth) | PEth at intake and at each check while drinking continues; AUDIT-C yearly | Completed today | PEth 122 ng/mL, from 284 |
| Medication safety | Naltrexone: liver tests and opioid exposure | Liver tests before starting, then at 1 to 3 months and every 6 to 12 months | Completed today | AST 41, ALT 37, GGT 68 U/L, improving; no opioid use |
| Medication safety | Thiamine | While drinking heavily | Completed today | Taking thiamine daily |
| Self-management | Coordinated specialty care engagement | Ongoing, for up to two to three years | Completed today | Care coordinator weekly; therapist twice; peer specialist introduced |

## Goal progress

- No return of psychotic symptoms and no readmission through six months, on the lowest effective antipsychotic dose. In progress; target 1889-07-20. **S**
- PHQ-9 score below 5 by six months. In progress; target 1889-07-20. **S**
- Reduce drinking to PEth below 20 ng/mL by six months. In progress; target 1889-07-20. **S**
- Weight gain under 5% and normal glucose, A1c and lipids at the 12-week check. In progress; target 1889-04-20. **S**
- Sleep about seven hours on most nights with regular times by three months. In progress; target 1889-04-20. **S**

## Medication changes

- Stopped: Propranolol 10 mg oral tablet, one tablet by mouth twice daily for akathisia **S**

## Guideline basis

- The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia, Third Edition (2020), American Psychiatric Association (American Journal of Psychiatry)
- Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder (2018), CANMAT and ISBD (Bipolar Disorders)
- Consensus development conference on antipsychotic drugs and obesity and diabetes (2004), American Diabetes Association, American Psychiatric Association, AACE, and NAASO (Diabetes Care)
- Recovery After an Initial Schizophrenia Episode (RAISE): coordinated specialty care for first-episode psychosis (2026), National Institute of Mental Health
- VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021), United States Department of Veterans Affairs and Department of Defense
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge

## Follow-up

- Three-month visit with fasting glucose, A1c, lipids, liver tests, PEth, and the PHQ-9. Care coordinator weekly; therapist every two weeks. **S**
- Next scheduled visit 1889-04-20: three-month review with the 12-week metabolic check. **S**
